10/28/2026
Pharma giants invest billions in psychedelics despite hurdles
Psychedelics like MDMA and psilocybin gain traction amid regulatory challenges.
Topic archive
psilocybin
8 stories
10/20/2026
Psychedelics fast-tracked by FDA under Trump order
Executive order allocates $50 million for psychedelic drug development, including ibogaine.
9/16/2026
Compass Pathways reports 52-week follow-up on psilocybin trial
Phase 3 trial shows potential benefits for treatment-resistant depression.
9/15/2026
Psychedelic therapies: potential and challenges
Exploring the promise and risks of psychedelic treatments in mental health.
8/18/2026
Puerto Rico advances psychedelic therapy research
Governor's order initiates ibogaine, MDMA, and psilocybin study
8/8/2026
Psyence BioMed focuses on psilocybin and ibogaine supply
The biotech firm aims for vertical integration in psychedelic therapeutics.
8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.
7/31/2026
Ibogaine research gains momentum in Mississippi
Mississippi explores ibogaine trials for addiction treatment, reflecting a shift towards health-centered drug policies.